Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 4
Submit an article Journal homepage
326
Views
23
CrossRef citations to date
0
Altmetric
Letters to the Editor

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

Ranjana H. AdvaniStanford University, Stanford, CaliforniaCorrespondence[email protected]
,
Fangxin HongDana Farber Cancer Institute, Boston, Massachusetts
,
Sandra J. HorningGenentech, South San Francisco, California, US
,
Brad S. KahlUniversity of Wisconsin, Madison, Wisconsin, US
,
Judith ManolaDana Farber Cancer Institute, Boston, Massachusetts
,
Lode J. SwinnenJohns Hopkins University, Baltimore, Maryland, US
,
Thomas M. HabermannMayo Clinic, Rochester, Minnesota, US
&
Kristen GanjooStanford University, Stanford, California
 show all
Pages 718-720 | Received 21 Jul 2011, Accepted 09 Sep 2011, Published online: 27 Apr 2012

References

  • Savage KJ. Aggressive peripheral T-cell lymphomas (specified and unspecified types). Hematology Am Soc Hematol Educ Program 2005; 267–277. 10.1182/asheducation-2005.1.267.
  • Jorgensen JM, Sorensen FB, Bendix K, . Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 2007; 48: 584–595.
  • Paydas S, Seydaoglu G, Ergin M, . The prognostic significance of VEGF-C and VEGF-A in non-Hodgkin lymphomas. Leuk Lymphoma 2009; 50: 366–373.
  • de Leval L, Rickman DS, Thielen C, . The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007; 109: 4952–4963.
  • Habermann TM, Weller EA, Morrison VA, . Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127.
  • D'Adamo DR, Anderson SE, Albritton K, . Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23: 7135–7142.
  • Choueiri TK, Mayer EL, Je Y, . Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol 2011; 29:632–638.
  • Miller KD, O'Neill A, Perez EA, . Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol 2008; 26: 520a.
  • Ganjoo KN, An CS, Robertson MJ, . Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998–1005.
  • Stopeck AT, Unger JM, Rimsza LM, . Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515. Blood 2010; 116: 591a.
  • Verma N, Swain SM. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side? J Clin Oncol 2011; 29: 603–606.
  • Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001; 280: C1375–C1386.
  • Pereg D, Lishner M. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword? Eur Heart J 2008; 29: 2325–2326.
  • Giordano FJ, Gerber HP, Williams SP, . A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc Natl Acad Sci U S A 2001; 98: 5780–5785.
  • Ranpura V, Pulipati B, Chu D, . Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 2010; 23: 460–468.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.